|
FDA Approves Pfizer’s Xeljanz As Second-Line RA Treatment
The FDA has approved Pfizer’s Xeljanz as a second-line treatment for adults with moderately to severely active rheumatoid arthritis (RA) who didn’t respond to or cannot take methotrexate.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives